Delivery Order SPE2DB22D9239-SPE2DB24FDH42
- Not listed
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $12,764.88 contract is for the supply of Perjeta 420 mg/14 ml vial, with a period of performance through June 25, 2024. This delivery order is part of a larger $499,999,999 indefinite delivery contract (IDC) held by DMS Pharmaceutical Group with the DLA under the SPE2DB program. This...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract award, valued at $12,415.50, is for the delivery of Perjeta, a 420 mg/14 ml vial medication, with an ultimate completion date of April 13, 2023. This delivery order is placed under DMS Pharmaceutical Group's $499,999,999 Indefinite Delivery Contract (IDC) with the DLA, which...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $25,529.76 contract is for the delivery of 420 mg/14 ml vials of the cancer drug Perjeta, with a performance period through December 12, 2024. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $36,458.16, is for the delivery of Perjeta 420 mg/14 ml vial, a prescription medication. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the DLA to issue firm...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $91,145.20 contract is for the supply of 420 mg/14 ml vials of the cancer drug Perjeta, with a period of performance through February 18, 2025. DMS Pharmaceutical Group holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the...
- This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract, valued at $17,019.84, is for the provision of Perjeta 420 mg/14 ml vials to support the recurring medical supply needs of military health facilities. DMS Pharmaceutical Group holds a significant indefinite delivery contract (IDC) with the DLA, valued at up to...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $8,509.92 contract is for the delivery of 420 mg/14 ml vials of the cancer drug Perjeta. This delivery order is part of a larger single-award indefinite delivery contract (IDC) valued up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program. This IDC...
- The Defense Logistics Agency awarded a $31,900.82 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 420 mg/14 mL vials of Perjeta, an oncology treatment medication. The award was issued on September 8, 2025, with an ultimate completion date of September 29, 2025, and carries no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's existing single-award...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $22,786.30 contract is for the delivery of 420 mg/14 ml vials of the cancer medication Perjeta, with a period of performance through February 6, 2025. DMS Pharmaceutical Group Inc. holds a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which...
- The U.S. Defense Logistics Agency (DLA) awarded a firm-fixed-price delivery order contract worth up to $25,529.76 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of 4563969889 - Perjeta 420 mg/14 ml vial, 14 ml, with a performance period through April 1, 2024. This delivery order is issued under DMS Pharmaceutical Group's indefinite delivery contract SPE2DB24FSW68 with DLA, which has a ceiling value of up to...
- SPE2DB22D9239Indefinite Delivery Contract
- SPE2DB22D9239-SPE2DB24FDH42Delivery Order
This is a firm-fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The $25,529.76 contract is for the delivery of Perjeta, a 420 mg/14 ml vial oncology medication, with a period of performance through April 9, 2024. This delivery order is placed against DMS Pharmaceutical Group's existing indefinite delivery vehicle (IDV) contract SPE2DB, a single-award contract valued up to $4,999,999 that enables the DLA to issue firm-fixed-price orders for a broad range of pharmaceutical products to support military medical facilities worldwide. DMS Pharmaceutical Group's woman-owned small business status has enabled direct awards for pharmaceutical Prime Vendor programs with the Department of Defense. There is no small business set-aside designation for this specific delivery order.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $25.5k | 3/19/24 |